• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab.

作者信息

Benhayoun Camélia, Duval Modeste Anne Bénédicte, Tamarit Clémence, Joly Pascal, Janela-Lapert Raphaël

机构信息

Dermatologie, C.H.U de Rouen, Rouen, France.

Anatomopathologie, C.H.U de Rouen, Rouen, France.

出版信息

JAAD Case Rep. 2024 Feb 29;50:44-46. doi: 10.1016/j.jdcr.2024.01.038. eCollection 2024 Aug.

DOI:10.1016/j.jdcr.2024.01.038
PMID:39040982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11260819/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/5f4ee235e015/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/38f4fdff81fb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/92cb1d022c13/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/5f0e7595b859/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/5f4ee235e015/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/38f4fdff81fb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/92cb1d022c13/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/5f0e7595b859/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f95/11260819/5f4ee235e015/gr4.jpg

相似文献

1
Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab.转移性汗腺癌：一例显示对帕博利珠单抗有客观反应的病例。
JAAD Case Rep. 2024 Feb 29;50:44-46. doi: 10.1016/j.jdcr.2024.01.038. eCollection 2024 Aug.
2
Metastatic Porocarcinoma Effectively Managed by Pembrolizumab.帕博利珠单抗有效治疗转移性汗孔癌
Cureus. 2021 Nov 29;13(11):e20004. doi: 10.7759/cureus.20004. eCollection 2021 Nov.
3
Diagnosis and Management of Porocarcinoma.汗孔癌的诊断与管理
Cancers (Basel). 2022 Oct 25;14(21):5232. doi: 10.3390/cancers14215232.
4
Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.微卫星不稳定性预测转移性黑色素瘤对抗PD1免疫疗法的反应。
Acta Dermatovenerol Croat. 2018 Dec;26(4):341-343.
5
Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer.米托坦联合免疫疗法治疗转移性肾上腺皮质癌患者的疗效
J Endocr Soc. 2019 Oct 11;3(12):2295-2304. doi: 10.1210/js.2019-00305. eCollection 2019 Dec 1.
6
Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab.使用帕博利珠单抗进行非标签免疫治疗使转移性神经内分泌肿瘤获得持续部分缓解。
Oncotarget. 2019 May 14;10(35):3302-3311. doi: 10.18632/oncotarget.26906.
7
A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.多学科方法治疗复发性转移性胸腺癌的独特病例：病例报告
Ther Adv Rare Dis. 2023 Aug 11;4:26330040231190661. doi: 10.1177/26330040231190661. eCollection 2023 Jan-Dec.
8
Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.转移性皮肤肉瘤患者对抗PD1免疫疗法的反应：病例报告与文献综述
Oxf Med Case Reports. 2020 Jan 31;2020(1):omz138. doi: 10.1093/omcr/omz138. eCollection 2020 Jan.
9
Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.采用常规分割放疗联合帕博利珠单抗治疗免疫治疗难治性转移性默克尔细胞癌
Front Oncol. 2019 Apr 5;9:223. doi: 10.3389/fonc.2019.00223. eCollection 2019.
10
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.评价不可切除黏膜黑色素瘤的免疫疗法疗效。
Cancer Immunol Immunother. 2019 Jul;68(7):1171-1178. doi: 10.1007/s00262-019-02351-7. Epub 2019 Jun 7.

本文引用的文献

1
Diagnosis and Management of Porocarcinoma.汗孔癌的诊断与管理
Cancers (Basel). 2022 Oct 25;14(21):5232. doi: 10.3390/cancers14215232.
2
Metastatic Porocarcinoma Effectively Managed by Pembrolizumab.帕博利珠单抗有效治疗转移性汗孔癌
Cureus. 2021 Nov 29;13(11):e20004. doi: 10.7759/cureus.20004. eCollection 2021 Nov.
3
Resolution of Metastatic Subungal Eccrine Porocarcinoma Treated with Intralesional Interleukin-2.转移性甲下小汗腺汗孔癌经病灶内注射白细胞介素 2 治疗后消退。
Curr Oncol. 2020 Dec 30;28(1):220-225. doi: 10.3390/curroncol28010024.
4
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab.对西妥昔单抗有反应的免疫治疗难治性、表皮生长因子受体过表达转移性汗孔癌
Eur J Cancer. 2021 Mar;146:84-86. doi: 10.1016/j.ejca.2021.01.012. Epub 2021 Feb 12.
5
Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab.帕博利珠单抗治疗转移性汗腺癌获完全影像学及临床缓解
BMJ Case Rep. 2019 Sep 5;12(9):e228917. doi: 10.1136/bcr-2018-228917.
6
Successful treatment of porocarcinoma with maxacalcitol and imiquimod.成功应用他卡西醇和咪喹莫特治疗派杰氏病。
Dermatol Ther. 2019 Mar;32(2):e12830. doi: 10.1111/dth.12830. Epub 2019 Feb 7.
7
Porocarcinoma; presentation and management, a meta-analysis of 453 cases.汗孔癌；临床表现与治疗，453例病例的荟萃分析。
Ann Med Surg (Lond). 2017 Jun 20;20:74-79. doi: 10.1016/j.amsu.2017.06.027. eCollection 2017 Aug.
8
Pembrolizumab (Keytruda).帕博利珠单抗（可瑞达）。
Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310. Epub 2016 Jul 11.
9
Intralesional Photodynamic Therapy for Eccrine Porocarcinoma.皮内光动力疗法治疗小汗腺汗孔癌
Dermatol Surg. 2015 Jul;41(7):853-4. doi: 10.1097/DSS.0000000000000389.
10
Metastasizing eccrine porocarcinoma: report of a case and review of the literature.
J Am Acad Dermatol. 1996 Nov;35(5 Pt 2):860-4. doi: 10.1016/s0190-9622(96)90105-x.